A subsidiary of United Pharmaceuticals received FDA approval for clinical trials of innovative drugs
July 14, 2025
Source: drugdu
62
On July 10, United Pharmaceutical (03933) issued an announcement, announcing that its wholly-owned subsidiary United Biotech received approval from the U.S. FDA on July 4, 2025 to register its Class 1 innovative drugUBT37034 injection is used in clinical trials for the indication of overweight or obesity.
The drug was developed by Federal Biotechnology and has independent intellectual property rights.It is a new type of peptide receptor agonist that can reduce body weight by selectively acting on neuropeptide Y2 receptors.
The announcement mentioned that preclinical animal model studies of UBT37034 showed that it can significantly reduce body weight when used in combination with GLP-1 analogs. The company said it will continue to focus on new product research and development, enhance its competitiveness and creativity in the biopharmaceutical industry, and is expected to create greater benefits for the company and its shareholders.
https://finance.eastmoney.com/a/202507103453263675.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- CureVac reaches settlement with BioNTech, Pfizer over COVID-19 vaccine patents August 9, 2025
- New progress in AIDS vaccine research and development! Vaccines may usher in new opportunities August 9, 2025
- Bio-thera receives approval for clinical trials of BAT1308 and other drugs August 9, 2025
- FDA approves Tongxin Medical’s BrioVAD to enter confirmatory clinical study August 9, 2025
- Fosun Pharma’s HLX43 for injection receives approval from the U.S. FDA for clinical trials August 9, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
